[go: up one dir, main page]

MX2009009574A - Tratamiento de melanoma. - Google Patents

Tratamiento de melanoma.

Info

Publication number
MX2009009574A
MX2009009574A MX2009009574A MX2009009574A MX2009009574A MX 2009009574 A MX2009009574 A MX 2009009574A MX 2009009574 A MX2009009574 A MX 2009009574A MX 2009009574 A MX2009009574 A MX 2009009574A MX 2009009574 A MX2009009574 A MX 2009009574A
Authority
MX
Mexico
Prior art keywords
compound
tautomer
salt
melanoma
treatment
Prior art date
Application number
MX2009009574A
Other languages
English (en)
Inventor
Carla C Heise
Marion Wiesmann
Paul Hollenbach
Daniel Menezes
Nancy Pryer
Katherine Rendahl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39500684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009574(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2009009574A publication Critical patent/MX2009009574A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los métodos para el tratamiento de melanoma incluyen administrar un compuesto de la Estructura (I), un tautómero del compuesto, una sal farmacéuticamente aceptable del compuesto, una sal farmacéuticamente aceptable del tautómero, o una mezcla de los mismos, a un sujeto. El compuesto, tautómero, sal del compuesto, sal de tautómero, o la mezcla de los mismos, se pueden utilizar para preparar medicamentos para el tratamiento de cáncer metastásico. La variable A tiene los valores definidos en la presente. (Ver fórmula I).
MX2009009574A 2007-03-09 2008-03-07 Tratamiento de melanoma. MX2009009574A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89404607P 2007-03-09 2007-03-09
US91140607P 2007-04-12 2007-04-12
PCT/US2008/056122 WO2008112509A1 (en) 2007-03-09 2008-03-07 Treatment of melanoma

Publications (1)

Publication Number Publication Date
MX2009009574A true MX2009009574A (es) 2009-09-16

Family

ID=39500684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009574A MX2009009574A (es) 2007-03-09 2008-03-07 Tratamiento de melanoma.

Country Status (11)

Country Link
US (1) US20100086518A1 (es)
JP (1) JP2010520881A (es)
KR (1) KR20090119768A (es)
AU (1) AU2008226582B2 (es)
BR (1) BRPI0808714A2 (es)
CA (1) CA2679268A1 (es)
CL (1) CL2008000681A1 (es)
MX (1) MX2009009574A (es)
RU (1) RU2009136669A (es)
TW (1) TW200843766A (es)
WO (1) WO2008112509A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
US8492374B2 (en) 2009-04-29 2013-07-23 Industrial Technology Research Institute Azaazulene compounds
EP2432451A2 (en) * 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
AU2014338549B2 (en) 2013-10-25 2017-05-25 Novartis Ag Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors
US10495138B2 (en) 2014-09-29 2019-12-03 Hewlett-Packard Development Company, L.P. Hinge assembly with compressible sleeve
WO2016054483A1 (en) 2014-10-03 2016-04-07 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3103450A1 (en) 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
AU2018274216A1 (en) 2017-05-24 2019-12-12 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
CN108610293B (zh) * 2018-06-15 2020-08-04 南京工业大学 一种采用微通道反应装置制备多韦替尼中间体的方法
WO2024097855A2 (en) * 2022-11-03 2024-05-10 University Of Florida Research Foundation, Incorporated Identification of small molecules that recruit and activate rnase l

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｆｇｆｒ３の阻害および多発性骨髄腫の治療
CA2656836A1 (en) * 2006-07-13 2008-01-17 Zymogenetics, Inc. Interleukin 21 and tyrosine kinase inhibitor combination therapy
WO2008013912A1 (en) * 2006-07-28 2008-01-31 Novartis Ag Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma

Also Published As

Publication number Publication date
BRPI0808714A2 (pt) 2014-08-12
CL2008000681A1 (es) 2008-10-24
US20100086518A1 (en) 2010-04-08
KR20090119768A (ko) 2009-11-19
CA2679268A1 (en) 2008-09-18
WO2008112509A1 (en) 2008-09-18
AU2008226582A1 (en) 2008-09-18
AU2008226582B2 (en) 2011-07-21
JP2010520881A (ja) 2010-06-17
RU2009136669A (ru) 2011-04-20
TW200843766A (en) 2008-11-16

Similar Documents

Publication Publication Date Title
MX2009009574A (es) Tratamiento de melanoma.
TNSN07294A1 (en) Treatment of metastasized tumors
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
TN2009000400A1 (en) Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha
MY150797A (en) Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
PH12016502354A1 (en) Pharmaceutical composition
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
PH12015500111A1 (en) Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
WO2010121675A3 (en) Thiazolyl-benzimidazoles
EP2215054B8 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
WO2008131946A3 (de) Substituierte amid-derivate
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2011044375A3 (en) Apogossypolone derivatives as anticancer agents
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
WO2010014798A3 (en) Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same
NZ593169A (en) Anticancer compounds
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
EA037533B9 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
MX2010009382A (es) Derivados de 4-aminociclohexano sustituidos para tratamiento de dolor.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal